Apharma

Apharma (Beijing) Co., Ltd. is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on targeting key signaling pathways in oncology and immunology, with a particular emphasis on the phosphoinositide 3-kinase (PI3K) family. Apharma's lead candidate, AP-001, is a selective PI3Kδ inhibitor currently being evaluated in clinical trials for various B-cell malignancies. The company leverages its proprietary drug discovery platform to develop a pipeline of high-potency, low-toxicity compounds aimed at addressing unmet medical needs in cancer and autoimmune disorders.